Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, Lopez-Yurda M, Beijnen JH, Huitema ADR, Witteveen PO, Steeghs N, van Haaften G, van Vugt MATM, de Ridder J, Opdam FL. Embaby A, et al. Among authors: van vugt matm. Gynecol Oncol. 2023 Jul;174:239-246. doi: 10.1016/j.ygyno.2023.05.063. Epub 2023 May 24. Gynecol Oncol. 2023. PMID: 37236033 Clinical Trial.
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga ANM, Polee M, Hollema H, van Vugt MATM, Schaapveld M, Willemse PHB; DoCaCel Study Group. Reyners AKL, et al. Among authors: van vugt matm. Ann Oncol. 2012 Nov;23(11):2896-2902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689176 Free article. Clinical Trial.
Comparison of Carboplatin With 5-Fluorouracil vs. Cisplatin as Concomitant Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
Hanemaaijer SH, Kok IC, Fehrmann RSN, van der Vegt B, Gietema JA, Plaat BEC, van Vugt MATM, Vergeer MR, Leemans CR, Langendijk JA, Voortman J, Buter J, Oosting SF. Hanemaaijer SH, et al. Among authors: van vugt matm, van der vegt b. Front Oncol. 2020 Jun 5;10:761. doi: 10.3389/fonc.2020.00761. eCollection 2020. Front Oncol. 2020. PMID: 32582534 Free PMC article.
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA. Fedoseienko A, et al. PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016. PLoS One. 2016. PMID: 27788210 Free PMC article.
Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
Hanemaaijer SH, van Gijn SE, Oosting SF, Plaat BEC, Moek KL, Schuuring EM, van der Laan BFAM, Roodenburg JLN, van Vugt MATM, van der Vegt B, Fehrmann RSN. Hanemaaijer SH, et al. Among authors: van der laan bfam, van vugt matm, van gijn se, van der vegt b. Oral Oncol. 2018 May;80:33-39. doi: 10.1016/j.oraloncology.2018.03.005. Epub 2018 Mar 27. Oral Oncol. 2018. PMID: 29706186
99 results